Prescribing overview
Glucocorticoid with distinct inhaled airway and oral intestinal uses; veterinary studies address different species and formulations.
Formulation determines delivery to airways or intestine.
Key prescribing checks
- Inhaled feline and equine studies reported adrenal-axis suppression.
- The canine IBD trial did not demonstrate fewer owner-reported adverse effects than prednisone.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
Extra-label veterinary evidence; not an animal product approvalInflammatory bowel disease, oral
Randomized canine study evaluated a powder-based oral preparation.
Use / indication source ↗Cats
Extra-label veterinary evidence; not an animal product approvalAsthma/chronic bronchitis, inhaled
Clinical observational study reported improvement and adrenal suppression in some cats.
Use / indication source ↗Horses
Extra-label veterinary evidence; not an animal product approvalSevere asthma, inhaled
Experimental trials used a dedicated investigational device; do not assume device equivalence.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Glucocorticoid anti-inflammatory action.
Absorption, distribution, metabolism and elimination
CYP3A4 metabolism creates interaction potential. Oral formulation and hepatic function influence exposure; animal inhalation studies show systemic endocrine effects.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Budesonide Inhalation Suspension
Human inhaled label; animal use is extra-label.
Contraindications · when not to use
- Ingredient hypersensitivity; not primary emergency asthma treatment.
Precautions & monitoring
- Infection, adrenal suppression and paradoxical bronchospasm require assessment.
Budesonide Delayed-Release Capsules / Entocort EC
Human oral delayed-release label; not a veterinary regimen.
Contraindications · when not to use
- Budesonide/component hypersensitivity.
Precautions & monitoring
- Systemic steroid effects and increased exposure with liver impairment remain possible.
Inhaled delivery does not eliminate systemic steroid effects.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Adrenal suppression can occur even with inhaled treatment.
Canine IBD trial did not show an adverse-effect advantage over prednisone.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No animal dosing is supplied. The veterinarian must select the exact formulation, delivery device and individual regimen.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Budesonide Inhalation Suspension
Human inhaled label; animal use is extra-label.
- Strong CYP3A4 inhibitors can increase corticosteroid exposure.
Budesonide Delayed-Release Capsules / Entocort EC
Human oral delayed-release label; not a veterinary regimen.
- Label advises avoiding CYP3A4 inhibitors, including itraconazole, erythromycin and cyclosporine.
Monitoring
Track respiratory or intestinal response according to indication.
Veterinarian assessment for infection and systemic steroid effects.
Client counseling
This is not an acute bronchodilator.
Do not change route, compound, device or chronic steroid therapy without the veterinarian.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Follow the exact capsule or inhalation-container storage and handling instructions.
Brands, formulations & ingredient identity
Active ingredients
Budesonide
Other searchable names: Pulmicort · Pulmicort Respules · Entocort EC
Oral delayed-release capsules, compounded oral products and inhalation suspensions are not interchangeable.
The canine IBD trial used pure powder-based oral budesonide, not proof of equivalence to an enteric human capsule.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Budesonide Inhalation Suspension
- Formulation
- Nebulizer inhalation suspension
- Label / product scope
- Human product
Human product; veterinary use requires a prescription. Respules-style formulation; verify product.
Product label / source ↗Budesonide Delayed-Release Capsules
- Formulation
- Oral delayed-release capsule
- Label / product scope
- Human product
Human product; veterinary use requires a prescription. Entocort EC-type presentation.
Product label / source ↗References & review status
Clinical reference updated October 26, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
